BACKGROUND Suboptimal platelet inhibition still represents an important challenge, especially for patients undergoing percutaneous coronary interventions (PCI). Chronic kidney disease (CKD) is a common comorbidity of patients with coronary artery disease, and may potentially influence platelet reactivity. So far only few studies have assessed the role of CKD on response to dual antiplatelet therapy with conflicting results. Therefore, the aim of our study was to evaluate the impact of CKD on platelet function in patients treated with dual antiplatelet therapy (DAPT) after a recent acute coronary syndrome or PCI.
BACKGROUND Suboptimal platelet inhibition still represents an important challenge, especially for patients undergoing percutaneous coronary interventions (PCI) . Chronic kidney disease (CKD) is a common comorbidity of patients with coronary artery disease, and may potentially influence platelet reactivity. So far only few studies have assessed the role of CKD on response to dual antiplatelet therapy with conflicting results. Therefore, the aim of our study was to evaluate the impact of CKD on platelet function in patients treated with dual antiplatelet therapy (DAPT) after a recent acute coronary syndrome or PCI.
METHODS Patients treated with DAPT (ASA + clopidogrel or ticagrelor) for an ACS or elective patients undergoing PCI were scheduled for platelet function assessment at 30-90 days post-discharge. Platelet function was assessed by whole blood impedance aggregometry (Multiplate Ò -Roche Diagnostics AG), HRPR was considered for ASPI test >862 AU*min (for ASA) and ADP test values >417 AU*min (for ADP-antagonists). Chronic renal failure was defined as an estimated glomerular filtration rate of 60 ml/min/1.73m2 or less, calculated by applying MDRD (Modification of Diet in renal Disease) formula.
RESULTS Our population included a total of 537 patients of which 308 (57.3%) received ASA and clopidogrel and 229 (42.6%) received ASA and ticagrelor. Patients with renal failure at baseline (101 out of 537, 18.8%) were older, with higher prevalence of history of hypertension, myocardial infarction and coronary artery bypass graft surgery. Moreover, they had a lower ejection fraction at baseline and were more often in therapy with diuretics, but less often with statins at admission. They had lower haemoglobin and higher glycated haemoglobin. HRPR was observed in 1.5% of patients treated with ASA with no difference according to renal function (p ¼ 0.18). HRPR for ADP-antagonists was observed in 23.7% of patients, with no difference according to renal function (p ¼ 0.50). This result was confirmed both with clopidogrel (31.9% versus 38%, p ¼ 0.41) and ticagrelor (13.1% versus 10.8%, p ¼ 0.99), also after correction for all baseline confounders (clopidogrel: adjusted OR
The absence of association between renal function and platelet reactivity was confirmed at linear regression analysis both with clopidogrel (r ¼ -0.04, p ¼ 0.52) and ticagrelor (r ¼ 0.006, p ¼ 0.92).
CONCLUSIONS In patients receiving dual antiplatelet therapy, chronic renal failure did not influence ADP-mediated platelet reactivity, with both ticagrelor or clopidogrel. No influence of chronic renal failure was found on the effectiveness of ASA. BACKGROUND Platelet Inhibition and Patient Outcomes Trial (PLATO trial) demonstrated that aspirin and ticagrelor were superior to aspirin and clopidogrel in reducing thrombotic complications. Continuous infusion of IIb/IIIa inhibitors (GPI) was used in 40% of patients with ticagrelor in the PLATO trial. However, the inhibition of platelet activity with ticagrelor starts rapidly and it is questionable whether continuous infusion of GPI with ticagrelor is needed, We, therefore, compared the impact of GPI bolus only vs. bolus and short infusion of GPI with ticagrelor on percent inhibition of platelet aggregation (%IPA) and outcome in patients with non-ST-segment myocardial infarction (NSTEMI).
METHODS A total of 70 patients with NSTEMI were randomized to ticagrelor 190 mg loading and eptifibatide bolus-only (TEP) vs. ticagrelor loading and eptifibatide bolus plus 2 h infusion(TEPI) administrated before stenting. Light transmission aggregometry was performed and %IPA was calculated at baseline, 2 h, 6 h, and 24 h using ADP, TRAP, collagen, and arachidonic acid (AA). Cardiac enzymes, hemoglobin and hematocrit were measured at baseline and 24 h. The event rates were determined at 30-day follow-up.
RESULTS
In patients randomized to TEP vs. TEPI, there were no significant difference in the %IPA values at 2 h and 6 h with ADP 5mM (100% AE 0.01 vs. 99% AE 0.25 and 99% AE 2.4 vs. 99% AE 1.2, respectively) and with ADP 20 mM (Fig. 1) , as well as with collagen. However, %IPA was lower at 24 h (still >60) compared with that at 2 h and 6 h. Percent IPA with TRAP 10 or 20 mM was higher at 6 h in patients randomized to TEPI vs. TEP (87% AE 13 vs. 74% AE 17; P<0.01, respectively).This had no bearing on outcomes since ADP was highly inhibited by ticagrelor at 6 h. There were no significant differences in troponin or hemoglobin levels among the groups. During follow-up, there was no stent thrombosis or myocardial infarction.
CONCLUSIONS Percent IPA values with ADP and collagen were not significantly different comparing ticagrelor with eptifibatide bolus only vs. ticagrelor and eptifibatide bolus plus 2 h infusion. Eptifibatide bolus only highly inhibited platelets aggregation while allowing bridging to the antiplatelet effect of ticagrelor and circumventing the need for continuous eptifibatide infusion. There was no significant difference in bleeding or MI between the 2 groups. 
